MedPath

Tyrosine

Generic Name
Tyrosine
Brand Names
Premasol, Clinimix E 2.75/5, Aminosyn-PF 7%, Primene, Clinimix 2.75/5, Trophamine 10 %, Plenamine, Olimel, Prosol, Clinisol 15, Periolimel, Travasol 10
Drug Type
Small Molecule
Chemical Formula
C9H11NO3
CAS Number
60-18-4
Unique Ingredient Identifier
42HK56048U
Background

Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

Indication

Tyrosine is claimed to act as an effective antidepressant, however results are mixed. Tyrosine has also been claimed to reduce stress and combat narcolepsy and chronic fatigue, however these claims have been refuted by some studies.

Associated Conditions
Acute Renal Dysfunction, Renal Failure, Chronic Renal Failure
Associated Therapies
Amino acid supplementation
Clinical Trials
Related News

Effects of Tyrosine Kinase Inhibitors on Liver Enzymes and Electrolytes

Conditions
Patients Diagnosed as Chronic Meyloid Leukemia
First Posted Date
2020-03-30
Last Posted Date
2022-02-22
Lead Sponsor
Assiut University
Target Recruit Count
40
Registration Number
NCT04326933
Locations
🇪🇬

Assiut University Hospital, Assiut, Egypt

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Phase 2
Active, not recruiting
Conditions
NSCLC
Interventions
First Posted Date
2020-03-24
Last Posted Date
2024-10-14
Lead Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Target Recruit Count
118
Registration Number
NCT04318938
Locations
🇩🇪

Universitätsmedizin Essen, Essen, Germany

🇩🇪

Evangelisches Krankenhaus Hamm, Hamm, Germany

🇩🇪

Lungenklinik Hemer, Hemer, Germany

and more 23 locations

Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

Phase 1
Terminated
Conditions
Chronic Myeloid Leukemia, Chronic Phase
Interventions
First Posted Date
2019-07-05
Last Posted Date
2022-07-01
Lead Sponsor
Milton S. Hershey Medical Center
Target Recruit Count
1
Registration Number
NCT04006847
Locations
🇺🇸

Penn State Cancer Institute, Hershey, Pennsylvania, United States

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: Zoledronic Acid 4 MG/100 ML Intravenous Solution [ZOMETA]
First Posted Date
2019-05-22
Last Posted Date
2025-05-21
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
100
Registration Number
NCT03958565
Locations
🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

🇺🇸

Lone Tree Medical Center, Lone Tree, Colorado, United States

Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia

Phase 2
Active, not recruiting
Conditions
Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
Procedure: Biospecimen Collection
Other: Drug Withdrawn
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2019-01-25
Last Posted Date
2025-03-19
Lead Sponsor
Children's Oncology Group
Target Recruit Count
110
Registration Number
NCT03817398
Locations
🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

🇺🇸

USA Health Strada Patient Care Center, Mobile, Alabama, United States

🇺🇸

Banner Children's at Desert, Mesa, Arizona, United States

and more 171 locations

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Phase 1
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
First Posted Date
2019-01-10
Last Posted Date
2019-01-10
Lead Sponsor
Clifford Hospital, Guangzhou, China
Target Recruit Count
150
Registration Number
NCT03799094
Locations
🇨🇳

Clifford Hospital, Guangzhou, China

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Phase 2
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Tyrosine Kinase Inhibitor
Minimal Residual Disease
Interventions
First Posted Date
2018-08-10
Last Posted Date
2018-08-10
Lead Sponsor
Nanfang Hospital, Southern Medical University
Target Recruit Count
82
Registration Number
NCT03624530
Locations
🇨🇳

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China

Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients

Phase 4
Conditions
Chronic Hepatitis b
Interventions
Drug: Granulocyte Macrophage Colony Stimulating Factor
First Posted Date
2017-11-06
Last Posted Date
2017-11-06
Lead Sponsor
Qin Ning
Target Recruit Count
15
Registration Number
NCT03332329

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Phase 2
Terminated
Conditions
EGFR Activating Mutation
Recurrent Non-Small Cell Lung Carcinoma
Stage IV Non-Small Cell Lung Cancer
Interventions
Other: Laboratory Biomarker Analysis
Drug: Chemotherapy
Biological: Nivolumab
Biological: Immunotherapy
Biological: Pembrolizumab
First Posted Date
2016-10-31
Last Posted Date
2024-06-28
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
19
Registration Number
NCT02949843
Locations
🇺🇸

Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia

Phase 2
Terminated
Conditions
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
First Posted Date
2016-04-06
Last Posted Date
2019-01-09
Lead Sponsor
Emory University
Target Recruit Count
9
Registration Number
NCT02730195
Locations
🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy